UCN2 and interstitial lung disease: Analysis of the ASS-ILD group indicated positivity for the anti-ARS antibody in all 53 patients (100%), for the anti-Jo-1 antibody in 37 patients (67.9%), for the anti-EJ antibody in nine patients (17%), for the anti-PL-12 antibody in five patients (9.4%), for the anti-PL-7 antibody in four patients (7.5%), and for the anti-SRP antibody in two patients (3.8%).